Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2020 06:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels...
December 23, 2019 20:31 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Acasti...
November 26, 2019 07:55 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
November 18, 2019 08:38 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes

Data from a new preclinical mouse study suggests a unique mechanism of CaPre compared to metformin and icosapent ethyl (VASCEPA®) in a diet-induced obesity animal model Preliminary, statistically...
November 13, 2019 07:55 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

LAVAL, Québec, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
November 07, 2019 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
November 06, 2019 09:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

LAVAL, Quebec, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and...
November 04, 2019 09:04 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®

LAVAL, Québec, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
October 01, 2019 09:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
September 30, 2019 08:35 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints...